TAC化疗方案联合西妥昔单抗、帕妥珠单抗治疗HER2阳性乳腺癌的效果观察  

Effect of TAC Chemotherapy Combined with Cetuximab and Pertuzumab in the Treatment of HER2-positive Breast Cancer

作　　者：呼延丽[1] Hu YanLi(Pharmacy Department of Gansu Provincial People's Hospital,Lanzhou 730000,Gansu Province,China)

机构地区：[1]甘肃省人民医院药剂科,甘肃兰州730000

出　　处：《中外医药研究》2024年第13期12-14,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:观察TAC化疗方案(多西他赛^(+)多柔比星^(+)环磷酰胺)联合西妥昔单抗、帕妥珠单抗治疗人表皮生长因子受体2(HER2)阳性乳腺癌的效果。方法:选取2020年4月—2021年12月甘肃省人民医院收治的HER2阳性乳腺癌患者68例作为研究对象,采用随机数字表法分成观察组与对照组,各34例。对照组采用TAC化疗方案治疗,观察组在对照组基础上采用西妥昔单抗、帕妥珠单抗双靶向治疗。比较两组治疗效果、免疫功能、新生血管指标。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P=0.028)。治疗前,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平比较,差异无统计学意义(P>0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平降低,观察组高于对照组,差异有统计学意义(P<0.05)。治疗前,两组三叶因子1(TFF1)、人类泛素偶联酶E2C(UBE2C)水平比较,差异无统计学意义(P>0.05);治疗后,两组TFF1、UBE2C水平降低,观察组低于对照组,差异有统计学意义(P<0.05)。结论:TAC化疗方案联合西妥昔单抗、帕妥珠单抗治疗HER2阳性乳腺癌的应用效果显著,可改善免疫功能及血管生成指标。Objective:To observe the effect of TAC chemotherapy regimen(Docetaxel^(+)Doxorubicin^(+)Cyclophosphamide)combined with cetuximab and pertuzumab in the treatment of human epidermal growth factor receptor 2(HER2)positive breast cancer.Methods:A total of 68 patients with HER2-positive breast cancer were selected as research objects at Gansu Provincial People's Hospital from April 2020 to December 2021,and were divided into observation group and control group by random number table method,with 34 cases in each group.The control group was treated with TAC chemotherapy,and the observation group was treated with cetuximab and pertuzumab on the basis of the control group.The therapeutic effect,immune function and neovascularization indexes were compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P=0.028).Before treatment,there was no significant difference in CD3^(+),CD4^(+),CD4^(+)/CD8^(+)levels between the two groups(P>0.05);after treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in both groups were decreased,and the observation group was higher than the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of trefoil factor 1(TFF1)and human ubiquitin coupling enzyme E2C(UBE2C)between the two groups(P>0.05);after treatment,the levels of TFF1 and UBE2C in the two groups were decreased,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).Conclusion:TAC chemotherapy combined with cetuximab and pertuzumab is effective in the treatment of HER2-positive breast cancer,and can improve immune function and angiogenesis indexes.

关 键 词：乳腺癌 西妥昔单抗 帕妥珠单抗 人表皮生长因子受体2 

分 类 号：R737.9[医药卫生—肿瘤]